Medicine Recommendations

Constipation

Opioid-induced constipation

Constipation in adults

Treating moderately to severely active ulcerative colitis in people aged 16 and over (NICE TA956)

NICE TA956 - Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over

Treating moderately to severely active ulcerative colitis - NICE TA792

NICE TA792 - Filgotinib for treating moderately to severely active ulcerative colitis

MHRA Drug Safety Update, 26 April 2023

JAK Inhibitors MHRA Drug Safety Update

Constipation in children

Bowel obstruction - colic associated with bowel obstruction AND GI secretions associated with bowel obstruction

Respiratory tract secretions in the last days of life

Prevention of recurrence of ulcerative colitis following surgery

Second line biologic for moderate to severe active ulcerative colitis ONLY where patients have had adalimumab 1st line .

First line biologic for moderate to severe active ulcerative colitis after the failure of conventional therapy (NICE TA329) and LSCMMG Recommendation

NICE TA329  Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

Bowel obstruction - colic associated with bowel obstruction AND GI secretions associated with bowel obstruction

Respiratory tract secretions in the last days of life

Use in high risk patients for prevention of recurrence or upon recurrence of Crohn's Disease following surgery.

Prevention of recurrence of ulcerative colitis following surgery

Second line biologic for moderate to severe active ulcerative colitis ONLY where patients have had adalimumab 1st line

Acute exacerbations of Ulcerative Colitis (NICE TA163)

NICE TA163 - Infliximab for acute exacerbations of ulcerative colitis

 Crohn's disease, 2nd line biologic (NICE TA187) and LSCMMG Recommendation

NICE TA187 - Infliximab and adalimumab for the treatment of Crohn's disease

Crohn's disease, 1st line biologic (NICE TA187) and LSCMMG Recommendation

NICE TA187 - Infliximab (review) and adalimumab for the treatment of Crohn's disease

First line biologic for moderate to severe active ulcerative colitis after the failure of conventional therapy (NICE TA329) and LSCMMG Recommendation

NICE TA329  Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

Crohn's disease
Ulcerative colitis

Constipation in adults

Constipation